聚酸盐,波洛克萨默和Brij对抗体稳定性的保护作用对不同接口的比较
Dominik Zürcher1, Severin Caduff1, Laetitia Aurand1
1Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland.
Journal of pharmaceutical sciences
|June 9, 2023
概括
配方科学家必须优化表面活性剂,以保持在各种接口上的治疗抗体稳定性. 纳米粒子分析揭示了常见的表面活性剂对固体液体接口的局限性,需要先进的配方策略.
科学领域:
- 生物制药配方 生物制药配方
- 蛋白质稳定性的工程.
- 表面化学 表面化学
背景情况:
- 治疗性蛋白质和抗体面临的稳定性挑战是由于在制造,储存和交付期间的多样化接口.
- 接口不稳定性可能会损害药物的疗效和保质期,需要仔细优化配方.
- 评估蛋白质稳定性的传统方法往往侧重于空气-水接口,可能会忽视固体-液体相互作用.
研究的目的:
- 评估常见的非离子表面活性剂在保护抗体药物免受各种固体-液体接口的有效性.
- 引入和验证基于纳米粒子的方法来评估接口抗体的不稳定性.
- 为了比较纳米粒子测试的性能与用于配方开发的传统动研究.
主要方法:
- 开发了一种基于纳米粒子的测试方法来评估抗体药物不稳定性.
- 对四种抗体药物进行了测试,对模型的疏水性,环烯-共聚合物 (COC) 和纤维素接口进行了测试.
- 评估了聚酸盐20,聚酸盐80,Poloxamer188和Brij 35的保护作用.
- 结果与传统的煽动研究进行了比较.
主要成果:
- 所有测试的非离子表面活性剂都在空气-水界面稳定了抗体.
- 没有表面活性剂提供了对水友性充电纤维素接口的保护.
- 聚酸盐和Brij 35对疏水界面 (COC和模型疏水材料) 提供了部分保护,但效果不如空气-水界面那么好.
- 波洛克萨默188在固体-液体接口上表现出极小的稳定作用.
结论:
- 传统的表面活性剂在保护抗体免受所有类型的固体-液体接口的限制.
- 基于纳米粒子的测试提供了一个补充的,高通量方法来评估蛋白质稳定性在相关的固体-液体接口.
- 这种方法可以帮助设计出可靠的配方,确保整个产品生命周期内的蛋白质稳定性.
相关概念视频
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
346
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
346
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
236
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
236


